Socioeconomic, health-care access and clinical determinants of disease severity in Multiple Sclerosis in Chile

• Published in: Multiple sclerosis and related disorders Vol. 78; p. 104918
• Main Authors: Ciampi, E, Soler, B, Uribe-San-Martin, R, Jürgensen, L, Guzman, I, Keller, K, Reyes, A, Bravo-Grau, S, Cruz, JP, Cárcamo, C
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.10.2023
• Subjects: Disability; Disease-modifying therapy; Health care access; Health policies; Multiple sclerosis; Socioeconomic condition; Socioeconomic indicator; Socioeconomic status; Disability; Multiple sclerosis; Socioeconomic status; Socioeconomic condition; Health care access; Disease-modifying therapy; Socioeconomic indicator; Health policies
• ISSN: 2211-0348; 2211-0356
• DOI: 10.1016/j.msard.2023.104918

•MS severity is determined by biological, socioeconomic, and healthcare factors.•Multicentric, observational, cross-sectional study including 604 patients in Chile.•Public healthcare and lower income were associated with worse MS severity.•Male sex, older age at onset and longer diagnostic delay were also risk factors.•Current treatment with high-efficacy therapy was a protective factor. MS severity may be affected by genetic, patient-related, disease-related and environmental factors. Socioeconomic status, including income and healthcare access, amongst others, may also have a role in affecting diagnostic delay or therapy prescription. In Chile, two main healthcare systems exist, public-healthcare and private-healthcare, nonetheless universal care laws (e.g., access to High Efficacy Therapy-HET), including both systems, have been recently enacted for people with MS. To assess the role of Socioeconomic Conditions (SEC), clinical variables and public health policies on the impact of disease severity of MS patients in Chile. Multicentric, observational, cross-sectional study including patients from two reference centres (1 national reference centre from the private-health system and 1 regional reference centre from the public-health system). SEC and clinical variables included healthcare insurance (private or public), subclassification of health insurance according to monthly income, sex, age at onset, diagnostic delay, disease duration, diagnosis before HET law (as a proxy of HET delay), and current HET treatment. Progression Index (PI), EDSS ≥6.0 and Progressive MS diagnosis were used as outcome measures. Multivariable binary logistic regression was performed. We included 604 patients (460 private-health, 144 public-health), 67% women, 100% white/mestizo, 88% RRMS, mean age 42±12 years, mean age at onset 32±11 years, mean disease duration 10±6 years, median diagnostic delay 0 (0–34) years, 86% currently receiving any DMT, 55% currently receiving HET, median EDSS at last visit of 2.0 (0–10), and median PI 0.17 (0–4.5). Lower monthly income was associated with higher EDSS and higher PI. In the multivariable analysis, public-healthcare (OR 10.2), being diagnosed before HET-law (OR 4.89), longer diagnostic delay (OR 1.26), and older age at onset (OR 1.05) were associated with a higher risk of PI>0.2, while current HET (OR 0.39) was a protective factor. Diagnosis before HET-law (OR 7.59), public-healthcare (OR 6.49), male sex (OR 2.56), longer disease duration (OR 1.2) and older age at onset (OR 1.1) were associated with a higher risk of Progressive MS. Public-healthcare (OR 5.54), longer disease duration (OR 1.14) and older age at onset (OR 1.08) were associated with a higher risk of EDSS ≥6.0 while current treatment with HET had a trend as being a protective factor (OR 0.44, p = 0.05). MS severity is impacted by non-modifiable factors such as sex and age at onset. Interventions focused on shortening diagnostic delay and encouraging early access to high-efficacy therapies, as well as initiatives that may reduce the disparities inherent to lower socioeconomic status, may improve outcomes in people with MS. [Display omitted]